{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:02:44Z","timestamp":1783083764292,"version":"3.54.6"},"reference-count":45,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH","award":["R01 AI157612"],"award-info":[{"award-number":["R01 AI157612"]}]},{"name":"NIH","award":["P51 OD011106"],"award-info":[{"award-number":["P51 OD011106"]}]},{"name":"NIH","award":["P51 OD011104"],"award-info":[{"award-number":["P51 OD011104"]}]},{"name":"NIH","award":["P51 OD011132"],"award-info":[{"award-number":["P51 OD011132"]}]},{"name":"NIH","award":["P51 OD011092"],"award-info":[{"award-number":["P51 OD011092"]}]},{"name":"NIH","award":["57407594"],"award-info":[{"award-number":["57407594"]}]},{"name":"NIH","award":["TI 07.001-80235CLJOW"],"award-info":[{"award-number":["TI 07.001-80235CLJOW"]}]},{"name":"DAAD Post-Doctoral Research Fellowship","award":["R01 AI157612"],"award-info":[{"award-number":["R01 AI157612"]}]},{"name":"DAAD Post-Doctoral Research Fellowship","award":["P51 OD011106"],"award-info":[{"award-number":["P51 OD011106"]}]},{"name":"DAAD Post-Doctoral Research Fellowship","award":["P51 OD011104"],"award-info":[{"award-number":["P51 OD011104"]}]},{"name":"DAAD Post-Doctoral Research Fellowship","award":["P51 OD011132"],"award-info":[{"award-number":["P51 OD011132"]}]},{"name":"DAAD Post-Doctoral Research Fellowship","award":["P51 OD011092"],"award-info":[{"award-number":["P51 OD011092"]}]},{"name":"DAAD Post-Doctoral Research Fellowship","award":["57407594"],"award-info":[{"award-number":["57407594"]}]},{"name":"DAAD Post-Doctoral Research Fellowship","award":["TI 07.001-80235CLJOW"],"award-info":[{"award-number":["TI 07.001-80235CLJOW"]}]},{"name":"German Center for Infection Research","award":["R01 AI157612"],"award-info":[{"award-number":["R01 AI157612"]}]},{"name":"German Center for Infection Research","award":["P51 OD011106"],"award-info":[{"award-number":["P51 OD011106"]}]},{"name":"German Center for Infection Research","award":["P51 OD011104"],"award-info":[{"award-number":["P51 OD011104"]}]},{"name":"German Center for Infection Research","award":["P51 OD011132"],"award-info":[{"award-number":["P51 OD011132"]}]},{"name":"German Center for Infection Research","award":["P51 OD011092"],"award-info":[{"award-number":["P51 OD011092"]}]},{"name":"German Center for Infection Research","award":["57407594"],"award-info":[{"award-number":["57407594"]}]},{"name":"German Center for Infection Research","award":["TI 07.001-80235CLJOW"],"award-info":[{"award-number":["TI 07.001-80235CLJOW"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Adenoviral vectors based on the human adenovirus species C serotype 5 (HAdV-C5) are commonly used for vector-based gene therapies and vaccines. In the preclinical stages of development, their safety and efficacy are often validated in suitable animal models. However, pre-existing neutralizing antibodies may severely influence study outcomes. Here, we generated a new HAdV-C5-based reporter vector and established a high-throughput screening assay for the multivalent detection of HAdV-C5-neutralizing antibodies in serum. We screened the sera of rhesus macaques at different primate centers, and of rabbits, horses, cats, and dogs, showing that HAdV-C5-neutralizing antibodies can be found in all species, albeit at different frequencies. Our results emphasize the need to prescreen model animals in HAdV-C5-based studies.<\/jats:p>","DOI":"10.3390\/vaccines12020155","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T09:43:22Z","timestamp":1706780602000},"page":"155","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["High-Throughput Screening for the Prevalence of Neutralizing Antibodies against Human Adenovirus Serotype 5"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4101-9280","authenticated-orcid":false,"given":"Jochen M.","family":"Wettengel","sequence":"first","affiliation":[{"name":"Division of Pathobiology and Immunology, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA"},{"name":"Institute of Virology, Technical University of Munich, 81675 Munich, Germany"},{"name":"German Center for Infection Research, Munich Partner Site, 81675 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6208-2270","authenticated-orcid":false,"given":"Hiroaki","family":"Naka","sequence":"additional","affiliation":[{"name":"Division of Genetics, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Dissen","sequence":"additional","affiliation":[{"name":"Molecular Virology Core, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Torgerson","sequence":"additional","affiliation":[{"name":"Molecular Virology Core, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Pounder","sequence":"additional","affiliation":[{"name":"Molecular Virology Core, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5429-0088","authenticated-orcid":false,"given":"Simon F.","family":"Mueller","sequence":"additional","affiliation":[{"name":"LABOKLIN GmbH, 97688 Bad Kissingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Mueller","sequence":"additional","affiliation":[{"name":"LABOKLIN GmbH, 97688 Bad Kissingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Hagen","sequence":"additional","affiliation":[{"name":"Institute of Virology, Technical University of Munich, 81675 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micah","family":"Brandt","sequence":"additional","affiliation":[{"name":"Division of Pathobiology and Immunology, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9421-1911","authenticated-orcid":false,"given":"Ulrike","family":"Protzer","sequence":"additional","affiliation":[{"name":"Institute of Virology, Technical University of Munich, 81675 Munich, Germany"},{"name":"German Center for Infection Research, Munich Partner Site, 81675 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7767-022X","authenticated-orcid":false,"given":"Benjamin J.","family":"Burwitz","sequence":"additional","affiliation":[{"name":"Division of Pathobiology and Immunology, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Zhao, Z., Anselmo, A.C., and Mitragotri, S. (2022). Viral vector-based gene therapies in the clinic. Bioeng. Transl. Med., 7.","DOI":"10.1002\/btm2.10258"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1128\/JVI.02055-12","article-title":"Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+T cells induced by different adenovirus vectors","volume":"87","author":"Tan","year":"2013","journal-title":"J. Virol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Farhad, T., Neves, K., Arbuthnot, P., and Maepa, M.B. (2022). Adenoviral vectors: Potential as anti-HBV vaccines and therapeutics. Genes, 13.","DOI":"10.3390\/genes13111941"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Chuang, I., Sedegah, M., Cicatelli, S., Spring, M., Polhemus, M., Tamminga, C., Patterson, N., Guerrero, M., Bennett, J.W., and McGrath, S. (2013). DNA prime\/adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 Induces sterile protection associated with cell-mediated immunity. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055571"},{"key":"ref_6","first-page":"155655","article-title":"Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans","volume":"7","author":"Jeyanathan","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"205ra134","DOI":"10.1126\/scitranslmed.3006843","article-title":"A Human type 5 adenovirus\u2013based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity","volume":"5","author":"Smaill","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"607333","DOI":"10.3389\/fimmu.2020.607333","article-title":"Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses","volume":"11","author":"Kerstetter","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1099\/vir.0.19497-0","article-title":"Genetic content and evolution of adenoviruses","volume":"84","author":"Davison","year":"2003","journal-title":"J. Gen. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF02789331","article-title":"Methods for construction of adenovirus vectors","volume":"3","author":"Graham","year":"1995","journal-title":"Mol. Biotechnol."},{"key":"ref_11","unstructured":"Hitt, M., Bett, J.A., Addison, C.L., Prevec, L., and Graham, F.L. (1995). Methods in Molecular Genetics, Elsevier."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"16.25.1","DOI":"10.1002\/0471142727.mb1625s78","article-title":"Production of recombinant adeno-associated viral vectors for in vitro and in vivo use","volume":"78","author":"Choi","year":"2007","journal-title":"Curr. Protoc. Mol. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-022-00503-y","article-title":"The use of viral vectors in vaccine development","volume":"7","author":"Travieso","year":"2022","journal-title":"NPJ Vaccines"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1016\/j.vaccine.2009.02.074","article-title":"In vitro and in vivo genetic stability studies of a human adenovirus type 5 recombinant rabies glycoprotein vaccine (ONRAB)","volume":"27","author":"Knowles","year":"2009","journal-title":"Vaccine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"veac067","DOI":"10.1093\/ve\/veac067","article-title":"High genetic stability of co-circulating human adenovirus type 31 lineages over 59 years","volume":"8","author":"Baier","year":"2022","journal-title":"Virus Evol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Chavda, V.P., Bezbaruah, R., Valu, D., Patel, B., Kumar, A., Prasad, S., Kakoti, B.B., Kaushik, A., and Jesawadawala, M. (2023). Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status. Vaccines, 11.","DOI":"10.3390\/vaccines11020432"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8934","DOI":"10.1128\/jvi.70.12.8934-8943.1996","article-title":"Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy","volume":"70","author":"Gao","year":"1996","journal-title":"J. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Ricobaraza, A., Gonzalez-Aparicio, M., Mora-Jimenez, L., Lumbreras, S., and Hernandez-Alcoceba, R. (2020). High-Capacity Adenoviral Vectors: Expanding the Scope of Gene Therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21103643"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/sj.gt.3302612","article-title":"Gutless adenovirus: Last-generation adenovirus for gene therapy","volume":"12","author":"Alba","year":"2005","journal-title":"Gene Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7866","DOI":"10.1073\/pnas.95.14.7866","article-title":"An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene","volume":"95","author":"Morsy","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.cmi.2021.10.005","article-title":"Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review","volume":"28","author":"Fiolet","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41591-021-01677-z","article-title":"Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: A randomized phase 4 trial","volume":"28","author":"Hou","year":"2022","journal-title":"Nat. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/COH.0b013e32833d2d2b","article-title":"Overview of STEP and Phambili trial results: Two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag\/pol\/nef subtype B HIV vaccine","volume":"5","author":"Gray","year":"2010","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1128\/JCM.41.11.5046-5052.2003","article-title":"Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: Addressing preexisting immunity to vaccine and gene therapy vectors","volume":"41","author":"Sprangers","year":"2003","journal-title":"J. Clin. Microbiol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Liu, Q., Nie, J., Huang, W., Meng, S., Yuan, B., Gao, D., Xu, X., and Wang, Y. (2012). Comparison of Two high-throughput assays for quantification of adenovirus type 5 neutralizing antibodies in a population of donors in China. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0037532"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/104303404322886147","article-title":"Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: Application in epidemiologic studies and in the design of adenovector vaccines","volume":"15","author":"Bett","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Bruder, J.T., Semenova, E., Chen, P., Limbach, K., Patterson, N.B., Stefaniak, M.E., Konovalova, S., Thomas, C., Hamilton, M., and King, C.R. (2012). Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses. PLoS ONE, 7.","DOI":"10.1371\/annotation\/c110beed-3cac-48db-9039-ba4498d5db50"},{"key":"ref_30","unstructured":"(2023, December 20). Untergasser, Production of Adenoviral Vectors for Application in Test Animals. Available online: https:\/\/www.untergasser.de\/lab\/protocols\/adeno_vectors_production_animal_v1_0.htm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/nprot.2007.135","article-title":"A protocol for rapid generation of recombinant adenoviruses using the AdEasy system","volume":"2","author":"Luo","year":"2007","journal-title":"Nat. Protoc."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1021\/es60130a004","article-title":"Trimmed Spearman-Karber method for estimating median lethal concentrations in toxicity bioassays","volume":"11","author":"Hamilton","year":"1977","journal-title":"Environ. Sci. Technol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Wettengel, J.M., Hansen-Palmus, L., Yusova, S., Rust, L., Biswas, S., Carson, J., Ryu, J., Bimber, B.N., Hennebold, J.D., and Burwitz, B.J. (2023). A Multifunctional and Highly Adaptable Reporter System for CRISPR\/Cas Editing. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24098271"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1038\/s41467-017-01953-y","article-title":"Hepatocytic expression of human sodium-taurocholate cotransporting polypeptide enables hepatitis B virus infection of macaques","volume":"8","author":"Burwitz","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"7670","DOI":"10.1038\/ncomms8670","article-title":"A palette of fluorescent proteins optimized for diverse cellular environments","volume":"6","author":"Costantini","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_36","first-page":"4048","article-title":"Identification of the human c-myc protein nuclear translocation signal","volume":"8","author":"Dang","year":"1988","journal-title":"Mol. Cell. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1021\/cb3002478","article-title":"Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate","volume":"7","author":"Hall","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"ref_38","unstructured":"Chng, J., Wang, T., Nian, R., Lau, A., Hoi, K.M., Ho, S.C., Gagnon, P., Bi, X., and Yang, Y. (2015). mAbs, Taylor & Francis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1038\/s41467-022-30593-0","article-title":"Long-term hepatitis B virus infection of rhesus macaques requires suppression of host immunity","volume":"13","author":"Biswas","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"10882","DOI":"10.1128\/JVI.76.21.10882-10893.2002","article-title":"Biology of ovine adenovirus infection of nonpermissive cells","volume":"76","author":"Kumin","year":"2002","journal-title":"J. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","article-title":"International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials","volume":"28","author":"Mast","year":"2010","journal-title":"Vaccine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1128\/CDLI.11.2.351-357.2004","article-title":"Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States","volume":"11","author":"Nwanegbo","year":"2004","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/jmv.23325","article-title":"Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China","volume":"84","author":"Yu","year":"2012","journal-title":"J. Med. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.3390\/v6052122","article-title":"Oncolytic virotherapy of canine and feline cancer","volume":"6","author":"Gentschev","year":"2014","journal-title":"Viruses"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.gt.3301608","article-title":"Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene","volume":"9","author":"Frisbie","year":"2002","journal-title":"Gene Ther."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/2\/155\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:53:18Z","timestamp":1760104398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/2\/155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["vaccines12020155"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12020155","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}